BioSpace News Archive

Seelos Therapeutics, Inc. released a letter to its stockholders from Raj Mehra, Ph.D., Chairman and Chief Executive Officer of Seelos, the text of which is copied below.

OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that the Company has received approval from the Alfred Human Research Ethics Committee (HREC) to conduct a Phase 1 clinical trial of drug candidate OLX75016 (the candidate of OLX702A) for the treatment of non-alcohol steatohepatitis (NASH).

CEL-SCI Corporation (NYSE American: CVM) reported financial results for the fiscal year ended September 30, 2023, as well as key clinical and corporate developments.

Insight Pharmaceuticals, a Prestige Consumer Healthcare Inc. company (“Insight”), is voluntarily recalling one lot of Americaine® 20% Benzocaine Topical Anesthetic Spray to the consumer level.

Kansas City Proton Institute (KCPI), the first physician-led proton therapy center in the Midwest, and Mevion Medical Systems announced today that the first four patients were treated at Kansas City Proton Institute on Dec. 19, with the MEVION S250i Proton Therapy System® .

The global gene editing market size is estimated to reach around USD 29.93 billion by 2032, increasing from USD 6.94 billion in 2022.

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”) noted today that its Founded Entity, Karuna Therapeutics, Inc., and (Nasdaq: KRTX) Bristol Myers Squibb (NYSE: BMY) announced that they have entered into a definitive merger agreement under which Bristol Myers Squibb has agreed to acquire Karuna for $330.00 per share in cash, for a total equity value of $14.0 billion, or $12.7 billion net of estimated cash acquired.

H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G pTau 217 Plasma assay for the fully automated LUMIPULSE G immunoassay systems.

Coherus BioSciences, Inc., announced that effective December 20, 2023, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 192,000 shares of the common stock of the Company to five newly hired employees with a per share exercise price of $1.94, the closing trading price on the grant date.

Iovance Biotherapeutics, Inc., a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte therapies for patients with cancer, announced that on December 21, 2023, the Company approved the grant of inducement stock options covering an aggregate of 44,175 shares of Iovance’s common stock to four new non-executive employees.